Founded in 2000, Galectin Therapeutics Inc. (GALT) is a biotechnology company based in Norcross, Georgia, United States. This company, listed on the NASDAQ exchange, is involved in conducting critical research and development in the healthcare industry, focusing on therapeutics that can fight chronic diseases and cancer.
Galectin Therapeutics emphasizes research on galectin proteins, carbohydrate-binding proteins in our bodies, which play a considerable role in controlling inflammation, fibrosis, and even the growth of tumors. It has its research on various types of diseases, including fibrotic diseases and cancer. GALT applies its deep knowledge in complex carbohydrate chemistry and galectin science to develop promising therapies for patients with few treatment options.
The company’s signature product is the belapectin (previously known as GR-MD-02), a compound that targets galectin-3. It is currently the most advanced drug in the company’s pipeline and is being studied for its potential in treating non-alcoholic steatohepatitis (NASH) with cirrhosis, a severe form of non-alcoholic fatty liver disease. This product would bring value to millions of patients who often have to resort to liver transplants.
Galectin Therapeutics is also exploring belapectin’s ability to improve outcomes for cancer patients, given the significant role galectin-3 plays in tumor angiogenesis, the process by which cancerous tumors access blood supply to fuel their growth. It is an exciting avenue in cancer treatment as it seeks to thwart tumor growth by inhibiting its access to blood supply.
Notably, Galectin Therapeutics collaborates with top-tier academic medical research centers, ensuring access to world-class expertise and resources, enhancing its drug development efforts. These collaborations have brought the company considerable recognition and established it as a leading player in researching and developing therapeutics based on galectin proteins.
Galectin Therapeutics Inc. may still be a small cap biotech company, but it is one with significant potential given the innovative work that they are doing. Despite not yet having a product on the market, Galectin's ongoing research into the medical applications of galectin proteins, the cutting-edge nature of their work, and their dedication to addressing severe medical conditions make it an intriguing company in the biotech sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Galectin Therapeutics has filed its Annual Report on Form 10-K for the fiscal year ending December 31, 2025, detailing the ongoing clinical development of its lead drug candidate, belapectin (GR-MD-02). Belapectin is a galectin-3 inhibitor focused on treating MASH with cirrhosis and certain cancer indications. The report highlights the completion of patient randomizations for the Phase 2b/3 NAVIGATE trial as of February 2023.
Galectin Therapeutics (NASDAQ:GALT) shares recently crossed above their 200-day moving average, reaching $3.86 before closing at $3.62, significantly higher than the $3.25 average. Analyst sentiment on GALT is mixed, with a consensus "Hold" rating and an $11.00 price target despite the company missing its last quarterly earnings estimate. Institutional investors currently hold about 11.68% of the company's stock.
Galectin Therapeutics (NASDAQ: GALT) announced its participation in the AASLD Liver Meeting 2026, featuring three presentations on belapectin for MASH cirrhosis and portal hypertension. The company will deliver an oral presentation and two poster presentations, including a "Poster of Distinction," highlighting new risk analyses from its NAVIGATE and GT-026 Phase 2b trials. Additionally, Galectin Therapeutics has submitted a registrational protocol for its Phase 3 trial of belapectin to the FDA.
Galectin Therapeutics Inc. announced its participation in the AASLD Liver Meeting 2026 with three presentations, including an oral presentation and a Poster of Distinction, focusing on belpectin's effectiveness in treating MASH cirrhosis and portal hypertension. The company also submitted a registrational protocol for a Phase 3 trial of belpectin to the FDA. These presentations highlight new risk analyses for noninvasive prediction of variceal development from previous trials, emphasizing belpectin's potential in an area with no approved treatments.
Galectin Therapeutics recently converted $105 million in debt to equity, which cleared its balance sheet but resulted in a 52% shareholder dilution and raised concerns about single financier dependency. The company's lead asset, Belapectin, showed positive subgroup data in Phase 2b/3 trials but missed primary endpoints, making a successful Phase 3 partnership critical for future value. Despite a risk-adjusted fair value suggesting potential upside, execution risks and funding needs temper immediate gains.
Galectin Therapeutics (NASDAQ:GALT) stock recently surpassed its 200-day moving average, reaching $4.02 before closing at $3.96. The company reported a quarterly loss of $0.14 per share, missing analyst estimates, and insiders have sold over 82,000 shares in the last three months. Analyst sentiment remains mixed, with an average "Hold" rating and an $11.00 consensus price target.